Publication Details
Abstract
The current investigation was aimed to study some important biomarkers in patients with chronic kidney disease. Between June and October of 2023, 80 patients were recorded for CKD cases at Al-Jumhuri Hospital and Azadi Teaching Hospital. In Kirkuk, Iraq, at private laboratories, experimental work was conducted. The present study's participants had been divided up as follows: 40 healthy volunteers as control group. 80 patients with CKD as a second group. The results showed that creatinine level in patients (6.37±1.56 mg/dl) was indicated a substantial (P≤0.05) rise when compared to the normal individuals (0.95±0.17 mg/dl). Urea level in patients (154.02±25.84 mg/dl) indicated a substantial (P≤0.05) rise when compared to the normal individuals (29.17±5.32 mg/dl). The Copeptin level in patients (6.13±0.49 pmol/L) was indicated a substantial (P≤0.05) rise when compared to the normal individuals (3.04±0.58 pmol/L). B2MG level in patients (3.47±0.35 ng/ml) was indicated a substantial (P≤0.05) rise when compared to the normal individuals (2.28±0.21 ng/ml). The MDA level in patients (3.94±0.31 nmol/ml) was indicated a substantial (P≤0.05) rise when compared to the normal individuals (1.47±0.7 nmol/ml). GSH level in patients (0.2573±0.052 nmol/ml) was indicated a substantial (P≤0.05) reduce when compared to the normal individuals (0.4831±0.052 nmol/ml). Based on the current results, Copeptin, B2MG, Malondialdehyde and glutathione, in addition to urea and creatine, can be considered important criteria for diagnosing chronic renal failure.